 - As a secondary objective, the efficacy of 3 s.c. doses of elsiglutide vs. placebo and vs. each other dose in the prevention of CID in colorectal cancer patients treated with 5-FU based chemotherapy FOLFOX or FOLFIRI given in combination with a monoclonal antibody will be explored. 